Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02208362CT.gov Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Grade II Glioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Arm 4: Il13Ra2-Specific Car Tcm Cells (this asset) | City of Hope Medical Center | P1 | CC · 43 |
| Perampanel | Mayo Clinic | P4 | B |
| FET | Thomas Hope | P2 | B |
| Pamiparib | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P1/2 | B |
| Selpercatinib | National Cancer Institute (NCI) | P2 | CCC |
| Ivosidenib | National Cancer Institute (NCI) | P2 | CCC |
| Olaparib | National Cancer Institute (NCI) | P2 | CCC |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | CCC |
| Infigratinib | Helsinn Healthcare SA | P1/2 | CC |
+7 more in the Grade II Glioma cohort
Other indications for Arm 4: Il13Ra2-Specific Car Tcm Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Glioma | — | P1 | CC · 43 |
| Grade III Glioma | — | P1 | CC · 43 |
| Glioblastoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Arm 4: Il13Ra2-Specific Car Tcm Cells in Grade II Glioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/arm-4-il13ra2-specific-car-tcm-cells-grade-ii-glioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →